Clinical trial enrollment at a rural satellite hospital during COVID-19 pandemic

Yub Raj Sedhai, Melissa Sears, Alessandra Vecchiè, Aldo Bonaventura, Joan Greer, Kathryn Spence, Hilary Tackett, Juanita Turner, Mary Pak, Nimesh Patel, Mellisa Black, George Wohlford, Rick Earle Clary, Christina Duke, Mary Hardin, Heather Kemp, Anna Priday, Earl Kenneth Sims Jr, Virginia Mihalick, Ai-Chen Ho, Ikenna Ibe, Mary Harmon, Roshanak Markley, Benjamin Van Tassell, Antonio Abbate, Yub Raj Sedhai, Melissa Sears, Alessandra Vecchiè, Aldo Bonaventura, Joan Greer, Kathryn Spence, Hilary Tackett, Juanita Turner, Mary Pak, Nimesh Patel, Mellisa Black, George Wohlford, Rick Earle Clary, Christina Duke, Mary Hardin, Heather Kemp, Anna Priday, Earl Kenneth Sims Jr, Virginia Mihalick, Ai-Chen Ho, Ikenna Ibe, Mary Harmon, Roshanak Markley, Benjamin Van Tassell, Antonio Abbate

Abstract

Introduction: Controlled clinical trials (CCTs) have traditionally been limited to urban academic clinical centers. Implementation of CCTs in rural setting is challenged by lack of resources, the inexperience of patient care team members in CCT conductance and workflow interruption, and global inexperience with remote data monitoring.

Methods: We report our experience during the coronavirus disease 2019 (COVID-19) pandemic in activating through remote monitoring a multicenter clinical trial (the Study of Efficacy and Safety of Canakinumab Treatment for cytokine release syndrome (CRS) in Participants with COVID-19-induced Pneumonia [CAN-COVID] trial, ClinicalTrials.gov Identifier: NCT04362813) at a rural satellite hospital, the VCU Health Community Memorial Hospital (VCU-CMH) in South Hill, VA, that is part of the larger VCU Health network, with the lead institution being VCU Health Medical College of Virginia Hospital (VCU-MCV), Richmond, VA. We used the local resources at the facility and remote guidance and oversight from the VCU-MCV resources using a closed-loop communication network. Investigational pharmacy, pathology, and nursing were essential to operate the work in coordination with the lead institution.

Results: Fifty-one patients with COVID-19 were enrolled from May to August 2020, 35 (69%) at VCU-MCV, and 16 (31%) at VCU-CMH. Among the patients enrolled at VCU-CMH, 37.5% were female, 62.5% Black, and had a median age of 60 (interquartile range 56-68) years.

Conclusion: Local decentralization of this trial in our experience gave rural patients access to a novel treatment and also accelerated enrollment and more diverse participants' representative of the target population.

Keywords: COVID-19; SARS-CoV-2; canakinumab; clinical trial; telemedicine.

Conflict of interest statement

The authors have no conflicts of interest to declare.

© The Association for Clinical and Translational Science 2021.

Figures

Fig. 1.
Fig. 1.
Schematic overlook of patient recruitment for the CAN-COVID trial at VCU-CMH. Due to the enormous spread of COVID-19, FDA released a guidance providing recommendations for remote/virtual assessments, including considerations for remote data collection. The possibility of remote working with clinical trials greatly helped decentralizing clinical trials that were highly needed due to the lack of effective drugs to treat COVID-19 patients. Legend. CAN-COVID: Study of Efficacy and Safety of Canakinumab Treatment for cytokine release syndrome (CRS) in Participants with COVID-19-induced Pneumonia. CCT: controlled clinical trial. COVID-19: coronavirus disease 2019. EHR: electronic health record. VCU-CMH: VCU Health Community Memorial Hospital. VCU-MCV: VCU Health Medical College of Virginia Hospital.

References

    1. Stasi C, Fallani S, Voller F, Silvestri C. Treatment for COVID-19: an overview. European Journal of Pharmacology 2020; 889: 173644.
    1. Scavone C, Brusco S, Bertini M, et al. Current pharmacological treatments for COVID-19: what’s next? British Journal of Pharmacology 2020; 177: 4813–4824.
    1. Hermine O, Mariette X, Tharaux PL, et al. Effect of Tocilizumab vs usual care in adults hospitalized with COVID-19 and moderate or severe pneumonia: a randomized clinical trial. JAMA Internal Medicine 2021; 181: 32–40.
    1. Group RC, Horby P, Lim WS, et al. Dexamethasone in hospitalized patients with Covid-19. New England Journal of Medicine 2021; 384: 693–704.
    1. Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the treatment of Covid-19 – final report. New England Journal of Medicine 2020; 383: 1813–1826.
    1. Kim SH, Tanner A, Friedman DB, Foster C, Bergeron CD. Barriers to clinical trial participation: a comparison of rural and urban communities in South Carolina. Journal of Community Health 2014; 39: 562–571.
    1. Izmailova ES, Ellis R, Benko C. Remote monitoring in clinical trials during the COVID-19 pandemic. Clinical and Translational Science 2020; 13: 838–841.
    1. What is Shortage Designation? [Internet] [cited Jan 4, 2021]. ()
    1. QuickFacts Mecklenburg County, Virginia [Internet] [cited Jan 4, 2021]. ()
    1. Conduct of Clinical Trials of Medical Products During the COVID-19 Public Health Emergency Guidance for Industry, Investigators, and Institutional Review Boards [Internet], March 2020, updated on December 4, 2020 [cited Jan 4, 2021]. ()
    1. Guidance on the Management of Clinical Trials during the COVID-19 (coronavirus) Pandemic Version 3 [Internet], 28/04/2020 [cited Jan 4, 2021]. ()
    1. Apostolaros M, Babaian D, Corneli A, et al. Legal, regulatory, and practical issues to consider when adopting decentralized clinical trials: recommendations from the clinical trials transformation initiative. Therapeutic Innovation & Regulatory Science 2020; 54: 779–787.
    1. Hollander JE, Carr BG. Virtually perfect? Telemedicine for Covid-19. New England Journal of Medicine 2020; 382: 1679–1681.

Source: PubMed

3
購読する